non-valvular
nonvalvular

Meta-Analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation.

Dabigatran vs. warfarin for stroke prevention with non-valvular atrial fibrillation (English)

In 1912 he spoke to the AGM of the British Medical Association on non-valvular cardiac disease.

In non-valvular AF, over 90% of stroke-causing clots that come from the heart are formed in the left atrial appendage.

More than 90% of cases of thrombi associated with non-valvular atrial fibrillation evolve in the left atrial appendage.

Treatment of atrial fibrillation Non-valvular atrial fibrillation is a common cause of ischaemic stroke.

In those with non-valvular atrial fibrillation it appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events.

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

On November 4, 2011, the U.S. FDA approved rivaroxaban for stroke prevention in people with non-valvular atrial fibrillation.

PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

This structure, located in the left atrium, is the place where a blood clot forms in more than 90% of cases in non-valvular (or non-rheumatic) atrial fibrillation.

Non-valvular atrial fibrillation and stroke prevention Position statement of the National Blood Pressure Advisory Committee of the National Heart Foundation.

The U.S. Food and Drug Administration (FDA) approved Pradaxa on October 19, 2010, for prevention of stroke in patients with non-valvular atrial fibrillation.

From August 1, the PBS will fund the once-daily Xarelto pill for people with non-valvular atrial fibrillation, a common heart rhythm irregularity that causes significant stroke risk.

For those with non-valvular atrial fibrillation, the NOACs (rivaroxaban, dabigatran, apixaban) are neither superior nor worse than warfarin in preventing non-hemorrhagic stroke and systemic embolic events.

Atritech's WATCHMAN LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation.

On March 18, 2008, the European Medicines Agency granted marketing authorisation for Pradaxa for the prevention of thromboembolic disease following hip or knee replacement surgery and for non-valvular atrial fibrillation.

On February 14, 2011, the American College of Cardiology Foundation and American Heart Association added dabigatran to their guidelines for management of non-valvular atrial fibrillation with a class I recommendation.

Dabigatran is an anticoagulant that works as a direct thrombin inhibitor, and does not require blood tests for INR monitoring, while offering similar results in terms of efficacy in the treatment of non-valvular AF.

Due to a limitation identified in long-term stability of the extended-release AZD0837 drug product, a follow-up study from ASSURE on stroke prevention in patients with non-valvular atrial fibrillation, was prematurely closed in 2010 after 2 years.

Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).

PROTECT AF evaluated the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Technology versus the current standard of care, warfarin, in patients with non-valvular atrial fibrillation at risk of stroke.

Studies have demonstrated that the annual incidence of a stroke in those with chronic non-valvular atrial fibrillation is 4.5%; oral warfarin decreases the incidence to 1.4%92. As well, after TIA or a stroke, warfarin decreases the risk of a second stroke from 12% to 4% 92.

Cardiologist Dr Andrew McCann said the drug, which will become available on the Pharamceutical Benefits Scheme from August 1, offered massive benefits for PE and DVT sufferers and could help prevent stroke in patients living with non-valvular atrial fibrillation - an irregular hear beat.

It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip or knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and one or more cardiovascular risk factors (at 300 mg/day).

To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation.

Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation.

"Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United States."

The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol.

Among people with nonvalvular atrial fibrillation, anticoagulation can reduce stroke by 60% while antiplatelet agents can reduce stroke by 20%.

The risk of stroke from nonvalvular AF can be estimated using the CHADS-VASc score.

Commentary on "Cardioversion followed by aspirin alone or with amiodarone was cost-effective for nonvalvular atrial fibrillation" Evidence-Based Medicine 1999;4(1):30.

"Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation."

Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Atrial Fibrillation III Study.

A new class of anticoagulant drugs, the direct thrombin inhibitors (Dabigatran), has recently arrived on the scene and shown efficacy in treating complications of nonvalvular chronic AF.

Pfizer Chief Executive Ian Read, in a statement, said he believes Eliquis "has the potential to transform the standard of care in stroke prevention in nonvalvular atrial fibrillation".

In October, the FDA approved the first of them, dabigatran etexilate, sold as Pradaxa, to prevent stroke and blood clots in patients with only nonvalvular atrial fibrillation- not those with artificial valves.

The most widely used anticoagulant to prevent thromboembolic stroke in patients with nonvalvular atrial fibrillation is the oral agent warfarin while a number of newer agents including dabigatran are alternatives which do not require prothrombin time monitoring.

The approval was supported by findings from the ROCKET-AF trial, which showed that rivaroxaban was as effective as warfarin at preventing stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

The FDA has approved rivaroxaban (Xarelto) for prevention of stroke in patients with nonvalvular atrial fibrillation, making it the first oral direct factor Xa inhibitor to be approved for stroke prevention.

A systematic review of risk factors for stroke in patients with nonvalvular AF concluded that a prior history of stroke or TIA is the most powerful risk factor for future stroke, followed by advancing age, hypertension, and diabetes.